Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has issued an announcement.
Venus Medtech (Hangzhou) Inc. has announced its 2024 Annual General Meeting scheduled for June 27, 2025, where key resolutions will be discussed and approved. These include the approval of the 2024 annual report, re-election of directors, appointment of auditors, and granting mandates for share issuance and repurchase, reflecting the company’s ongoing strategic management and governance efforts.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company based in the People’s Republic of China, primarily operating in the medical technology industry. It focuses on developing and manufacturing innovative medical devices, particularly in the cardiovascular sector, aiming to address unmet clinical needs and improve patient outcomes.
Average Trading Volume: 8,866,567
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.06B
Find detailed analytics on 2500 stock on TipRanks’ Stock Analysis page.